FDA Approvals and Expansions In May, the FDA approved the mRNA-1345 RSV vaccine (mResvia) from Moderna for people ages 60 and ...

The vaccine approved for emergency authorization is manufactured by pharmaceutical company Novavax, with updated vaccines from Pfizer and Moderna available for use ... “It’s not bivalent, which is the ...

who added that the new vaccine also seems to achieve a more durable response than Moderna's first bivalent shot mRNA-1273.211, based on the original SARS-CoV-2 and the Beta variant. With Omicron ...

mRNA-1083 consists of components of mRNA-1010, Moderna’s vaccine candidate for seasonal influenza, and mRNA-1283, its next-generation bivalent COVID-19 vaccine, which targets updated variants of ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Vaccines that prevent smallpox and mpox come in two varieties. One uses a single shot of a live virus but carries the risk of ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...